GlobeNewswire News Roomยท2025-08-02 05:54Group 1: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - The class period for Sarepta is from June 22, 2023, to June 24, 2025, with a lead plaintiff deadline of August 25, 2025 [2] - The lawsuit alleges that Sarepta made materially false and misleading statements regarding its gene therapy ELEVIDYS, which was intended to treat Duchenne muscular dystrophy, leading investors to believe it was safe and had a positive revenue outlook [2] - Significant safety risks associated with ELEVIDYS were not disclosed, including severe side effects that led to the halting of trials and regulatory scrutiny [2][3] - Following the announcement of a patient death related to ELEVIDYS, Sarepta's stock price fell by $27.81 (27.44%) to close at $73.54 on March 18, 2025 [3] - Subsequent disclosures of additional patient deaths and regulatory investigations resulted in further stock price declines, with a notable drop of $15.24 (42.12%) to close at $20.91 on June 15, 2025 [3] Group 2: Petco Health and Wellness Company, Inc. (NASDAQ:WOOF) - The class period for Petco is from January 14, 2021, to June 5, 2025, with a lead plaintiff deadline of August 29, 2025 [4] - The lawsuit claims that Petco made materially false and misleading statements about its business operations, particularly regarding the sustainability of pandemic-related growth and the viability of its premium pet food business model [4][5] - Defendants allegedly overstated Petco's ability to achieve sustainable, profitable growth, with a specific reference to a share price of $95.85 on May 21, 2025 [5]